Haemophilia care then, now and in the future

@article{Oldenburg2009HaemophiliaCT,
  title={Haemophilia care then, now and in the future},
  author={Johannes Oldenburg and Gerry Dolan and George Lemm},
  journal={Haemophilia},
  year={2009},
  volume={15}
}
Summary.  Epidemiological data show the benefits of dramatically improved haemophilia care in all life‐stages. There are improved administration techniques and dosing regimens, a shift from on‐demand treatment to prophylaxis, successful treatment protocols for immune tolerance induction in patients with inhibitors and enhanced approaches to overall patient management. Improvements also include the introduction of virus inactivation methods for plasma derived clotting factor concentrates and the… Expand
The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges.
TLDR
Recent progresses in the management of hemophilia are analyzed and opportunities and challenges are discussed, characterized by an easier route of administration, low immunogenicity, and, regarding gene therapy and cell-based treatments, potential long-term protection from bleeding after a single treatment course. Expand
The History and Evolution of the Clinical Effectiveness of Haemophilia Type A Treatment: A Systematic Review
TLDR
The aim of this review was to assess the evidence of different treatment options for haemophilia type A over the past four decades, focusing on the most important technological advances that have influenced the natural course of this “royal disease”. Expand
Current and Future Options of Haemophilia A Treatments
TLDR
It can be expected that patients with hemophilia will benefit significantly from the new treatment options and that the protection against bleeding and joint damage as well as the quality of life will increase. Expand
Haemophilia B: impact on patients and economic burden of disease.
TLDR
Evidence demonstrates that primary prophylaxis is the optimal strategy for replacing missing clotting factor IX (FIX) and managing haemophilia B and any reduction in FIX replacement dosing frequency is expected to improve patient adherence and contribute to improved clinical outcomes, further supporting the cost-effectiveness of such interventions. Expand
Novel therapies and current clinical progress in hemophilia A
TLDR
The development of extended half-life products, a bispecific antibody which mimics the coagulation function of factor VIII (FVIII) and inhibition of anticoagulation proteins such as antithrombin with antibodies, aptamers or RNA interference technology have offered novel therapeutic approaches to overcome some of these existing challenges. Expand
Comorbidities and inhibitors in adult patients with haemophilia: issues, costs and management strategies
TLDR
Several topics relevant to the clinical management of adult patients with haemophilia were examined in a symposium held on 11 February 2015 in Helsinki, Finland, in conjunction with the 8th Annual Congress of the European Association for Haemophilias and Allied Disorders. Expand
Thrombin generation testing in haemophilia comprehensive care centres
  • Y. Dargaud, C. Négrier
  • Medicine
  • Haemophilia : the official journal of the World Federation of Hemophilia
  • 2010
TLDR
An expanding interest of haematologists for thrombin generation testing (TGT) reflects the need for new laboratory tools able to evaluate the overall coagulating capacity of patients, and unmet laboratory needs in haemophilia are reviewed. Expand
The pharmacist’s role in managing hemophilia
TLDR
Present-day management of hemophilia is better than in previous times in terms of safety, effective treatments, and reduced disability, according to this review. Expand
Characteristics of Older Patient with Haemophilia
TLDR
The discovery of factor concentrates improved quality of life and prolong life expectancy and the overall haemophilic life expectancy was reported to be 71 years in Italy that is approaching the general male population. Expand
8 Characteristics of Older Patient with Haemophilia
1.1 Life expectancy in patients with haemophilia Until 1960 haemophilia was a life-threatening disease with limited treatment options as splints, icepacks and bed rest. With the discovery of factorExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain.
  • J. Batlle, A. Villar, +15 authors C. Aguilar
  • Medicine
  • Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • 2008
TLDR
It is suggested that a gradual switch to recombinant concentrates may be a beneficial decision for patients with haemophilia and for the National Health Service. Expand
The changing prognosis of classic hemophilia (factor VIII "deficiency").
OBJECTIVE To estimate relative risk of mortality and median life expectancy for patients with classic hemophilia by a life-table analysis, taking into account deaths that may have occurred in infancyExpand
Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment
TLDR
Novel clotting factor formulations based on PEGylated liposomes with prolonged activities are being tested in the clinic, and are yielding encouraging results, which justifies the search for novel cost‐effective therapies and ultimately a cure. Expand
Changes in the life expectancy of patients with severe haemophilia A in Finland in 1930‐79
TLDR
The overall annual death rate of patients without inhibitors was only 1.2 per thousand in 1970–79, suggesting that at the present time the life expectancy of patients who do not develop inhibitors does not markedly differ from that of the general male population. Expand
Intracranial haemorrhages in French haemophilia patients (1991–2001): clinical presentation, management and prognosis factors for death
TLDR
Information concerning recognition and management of these episodes, not only in severe haemophilia, but also in moderate and mild forms, should be regularly supplied to paediatricians in maternity and physicians from emergency units, as well as to patients and their relatives. Expand
Mortality and causes of death in patients with hemophilia, 1992–2001: a prospective cohort study 1
TLDR
Mortality of patients with hemophilia is still increased; this is largely because of the consequences of viral infections, as well as in patients not affected by viral infections. Expand
Factors predictive of death among HIV‐uninfected persons with haemophilia and other congenital coagulation disorders
TLDR
It is concluded that causes of death and prognostic factors for current HIV‐uninfected haemophilia patients are similar to those noted before the HIV epidemic and better understanding, prevention and control of neutralizing antibodies and hepatitis infections may substantially improve longevity for people with haemolysis. Expand
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
TLDR
Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in young boys with severe hemophilia A. Expand
Consensus perspectives on prophylactic therapy for haemophilia: summary statement
TLDR
Participants in an international conference on prophylactic therapy for severe haemophilia developed a consensus summary of the findings and conclusions of the conference, and agreed upon revised definitions for primary and secondary Prophylaxis and made recommendations concerning the need for an international system of pharmacovigilance. Expand
Home transfusion for patients with hemophilia A.
TLDR
Until prophylactic therapy becomes feasible, home transfusion is a reasonable substitute for hemophiliac patients deficient in antihemophilic factor, according to 18 months' experience. Expand
...
1
2
3
4
...